BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse ...
Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced ...
Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today ...
BOSTON--(BUSINESS WIRE)--Dapu Biotechnology (DPBIO), an industry leader in droplet microfluidic technology, and Leveragen, Inc., a Boston-based biotech developing advanced genetic models for antibody ...
Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in ...
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...
This article and associated images are based on a poster originally authored by Mette Juul Jacobsen, Anastasios Glaros, Abrahan Hernandez-Hernandez, Anja Mezger, Tina Friis, and Peter Mouritzen and ...
SAN DIEGO, CALIF. — GemPharmatech, a global leader in preclinical research solutions and genetically-engineered mouse models, today announced a collaboration with Memorial Sloan Kettering Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results